CORT insider sale: 2,200 shares planned for 10/10/2025 ($192,588)

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) reported a Form 144 notice for the proposed sale of 2,200 common shares with an aggregate market value of $192,588, scheduled for 10/10/2025 on NASDAQ. The filing states the shares were acquired under an option granted on 08/20/2018 and payment will be in cash. The filing also discloses three prior sales by the same seller: 2,200 shares on 07/10/2025 for $156,376, 2,200 shares on 08/11/2025 for $159,060, and 2,200 shares on 09/10/2025 for $159,390, totaling $474,826 in gross proceeds. Outstanding shares are listed as 105,371,729, making the scheduled sale a very small fraction of total shares outstanding.

Positive

• Planned sale size is minimal at 2,200 shares versus 105,371,729 outstanding (~0.0021%)
• Acquisition and payment details disclosed (option granted 08/20/2018, cash payment)
• Recent sales fully reported, totaling $474,826 over three months, improving transparency

Negative

• Repeated insider sales of 2,200 shares in 07/10/2025, 08/11/2025, and 09/10/2025 may warrant attention despite small size
• No Rule 10b5-1 plan date provided; if a plan exists, its adoption date is not disclosed in this filing

Insights

Corporate Governance Analyst

Small, routine insider sales disclosed; not structurally dilutive.

The filing shows a planned sale of 2,200 shares on 10/10/2025 and three recent insider sales totaling 6,600 shares and $474,826 in gross proceeds over the prior three months. The shares were acquired under an option granted on 08/20/2018, and payment for the scheduled sale is cash.

At an issuance base of 105,371,729 outstanding shares, the single planned sale represents roughly 0.0021% of the float, indicating limited immediate market impact; monitor for any patterned selling beyond the disclosed transactions over the next 30–90 days.

Insider Trading Compliance Expert

Disclosure aligns with Rule 144 mechanics and includes a 10b5-1 representation clause.

The filer asserts the Rule 144 representation that no undisclosed material adverse information is known and provides acquisition details (option grant date and cash payment). The form includes a caution about Rule 10b5-1 if a trading plan exists, but no plan date is provided in the filing.

If a written trading plan had been adopted, a plan adoption date would be expected; absence of that date means stakeholders should only rely on the explicit sale dates disclosed within the form for near-term monitoring.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2200	192588.00	105371729	10/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/10/2025	Option Granted - 08/20/2018	Issuer			2200	10/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel Swisher 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/10/2025	2200	156376.00
Daniel Swisher 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/11/2025	2200	159060.00
Daniel Swisher 101 Redwood Shores Parkway Redwood City CA 94065	Common	09/10/2025	2200	159390.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Corcept Therapeutics (CORT) Form 144 disclose?

The form discloses a proposed sale of 2,200 common shares valued at $192,588 scheduled for 10/10/2025, with acquisition by an option granted on 08/20/2018 and cash payment.

How many shares has the filer sold recently and for how much?

The filing lists three prior sales of 2,200 shares each on 07/10/2025, 08/11/2025, and 09/10/2025, with gross proceeds totaling $474,826.

Will this planned sale materially affect CORT's market capitalization?

No, the scheduled sale of 2,200 shares represents about 0.0021% of the 105,371,729 shares outstanding, so it is not materially dilutive.

Were the shares being sold originally acquired by purchase, gift, or option?

The securities were acquired via an option granted on 08/20/2018, per the filing.

Does the filing state whether there is a Rule 10b5-1 trading plan?

No adoption date for a Rule 10b5-1 plan is provided in the filing; the form contains the standard representation clause but does not list a plan date.